C4BPαZ Inhibitors

Chemical inhibitors classified as C4BPαZ Inhibitors are compounds that can influence the activity, stability, or expression of the protein C4b-binding protein alpha chain, which is a regulatory component of the complement system. The complement system is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from the body, promote inflammation, and attack the pathogen's cell membrane. C4BPα acts as a control protein that inhibits the classical and lectin pathways of complement activation by serving as a cofactor for the serine protease factor I, which inactivates C4b.

The inhibitors listed above are not directly targeting C4BPα but rather are capable of indirectly affecting its activity by modulating related pathways or processes. For instance, PI3K inhibitors can attenuate the classical complement pathway at an upstream stage, which can lead to a decreased need for the regulatory function of C4BPα. Similarly, inhibitors of the NF-κB pathway may alter the transcription of genes encoding complement proteins, thereby influencing the levels and activity of C4BPα indirectly. Inhibitors of the JAK-STAT and MAPK/ERK pathways can affect the signaling that may regulate the expression of C4BPα as well as other components of the complement system. Anti-inflammatory agents like cyclooxygenase inhibitors and leukotriene B4 receptor antagonists can modulate the inflammatory response, which is closely tied to the activation of the complement system, thus affecting the functional context in which C4BPα operates.